Liraglutide
لیراگلوتاید
🍽️ Alimentary Tract And MetabolismGLP-1 receptor agonist
Market / country: 🇺🇸 USA
Victoza (US)
🧮 Dose calculator
Type 2 diabetes mellitus · Regimen source: FDA Victoza · 2.1
- • 0.6 mg is only for GI tolerability. If more than 3 days missed, restart at 0.6 mg. FDA Victoza · 2.1FDA Victoza · 2.2
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ Personal or family history of medullary thyroid carcinoma or MEN 2; serious hypersensitivity. FDA Victoza · 4
Warnings
- • Boxed warning: thyroid C-cell tumours in rodents; contraindicated with MTC or MEN 2 history. FDA Victoza · Boxed Warning
Formulations
- 6 mg/mL pen (18 mg/3 mL; doses 0.6, 1.2, 1.8 mg) — injection 🇺🇸 USA FDA Victoza · 3
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Victoza · 8.1
“Risk Summary Based on animal reproduction studies, there may be risks to the fetus from exposure to VICTOZA during pregnancy.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Victoza · 8.2
“Risk Summary There are no data on the presence of VICTOZA in human milk, the effects on the breastfed infant, or the effects on milk production.”
- 👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Victoza · 8.4
“The safety and effectiveness of VICTOZA as an adjunct to diet and exercise to improve glycemic control in type 2 diabetes mellitus have been established in pediatric patients 10 years of age and older.”
- 👴 Older adultsNo specific problem stated
Label: no specific difference or dose adjustment stated for older adults. FDA Victoza · 8.5
“No overall differences in safety or effectiveness for VICTOZA have been observed between patients 65 years of age and older and younger patients.”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)NDA022341
- DailyMed (FDA label)FDA Victoza
- MedlinePlus (NIH)Liraglutide Injection
- WHO ATC/DDDA10BJ02
- Darooyab (Iran)Liraglutide
🇮🇷 Registered in Iran Darooyab · G-4899/Liraglutide
Dosage forms with Iranian generic codes, per Darooyab.
- 22666 · LIRAGLUTIDE INJECTION, SOLUTION 6 mg/1mL 3ML PEN (VICTOZA) · قلم تزریقی لیراگلوتاید ۶ میلیگرم / ۱ میلیلیتر ۳ میلیلیتر (ویکتوزا)
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Victoza · 3FDA Victoza · 2.1FDA Victoza · 2.2FDA Victoza · 4FDA Victoza · Boxed WarningFDA Victoza · 8.1FDA Victoza · 8.2FDA Victoza · 8.4FDA Victoza · 8.5FDA Victoza · SPL approval / marketing category
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-4899/Liraglutide
- Clinical review⚠ Unverified